Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance
| Autor: | Nieves Martell-Claros, Ines Gil-Gil, Emilio Márquez-Contreras, Eugenio Sanchez-López, Vicente Francisco Gil-Guillén, Mariano De La Figuera-Von Wichmann, Sara Márquez-Rivero |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Health-related quality of life 030204 cardiovascular system & hematology Non-valvular atrial fibrillation 03 medical and health sciences 0302 clinical medicine Rivaroxaban Quality of life Older patients Internal medicine Atrial Fibrillation Humans Medicine In patient Longitudinal Studies Prospective Studies 030212 general & internal medicine Aged business.industry Therapeutic compliance Public Health Environmental and Occupational Health Anticoagulants Preventing stroke Compliance (physiology) Multicenter study Spain Stroke prevention Quality of Life Physical therapy Patient Compliance Female Orals anticoagulants business Previously treated medicine.drug |
| Zdroj: | QUALITY OF LIFE RESEARCH r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau Instituto de Salud Carlos III (ISCIII) |
| ISSN: | 1573-2649 0962-9343 |
| DOI: | 10.1007/s11136-016-1489-x |
| Popis: | To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance. Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL. Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53-88.57%) (n = 309) and 80% (CI 74.65-85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL). QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|